Dementia doesn't just erode memory -- it also changes behavior and mental health. A study shows the brain's salience network and tau protein may be involved.
An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...
DEPTAC. Based on PROTACs, or protein-targeting chimeras, D20, a dephosphorylation-targeting chimera, delivers PP1 to tau. The C-terminal tail (gray) helps the construct enter cells. [Courtesy of Xiao ...
Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.
An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...
AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.
AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...
Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...
(IN BRIEF) An international team of researchers has made a significant breakthrough in Alzheimer’s drug development with the introduction of RI-AG03, a novel peptide inhibitor that targets and ...
The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...
The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized ...